Latest Updates of Companies in the Biologics Contract Manufacturing Market
| Company | Headquarters | Latest Update |
| Thermo Fisher Scientific | United States | In April 2026, Thermo Fisher Scientific Inc. opened its U.S. Bioprocess Design Center (BDC) at the company’s Plainville, Mass., site, expanding the facility to support customers in developing and scaling biologics. |
| AGC Biologics | United States | AGC Biologics is a worldwide CDMO offering development and manufacturing solutions for protein-based biologics and well-developed therapies. |
| Catalent, Inc. | United States | In October 2026, GelMEDIX Inc. and Catalent, Inc. announced a worldwide collaboration to access Catalent’s GMP-induced pluripotent stem cells (iPSC) and Catalent’s cell therapy manufacturing expertise and capabilities to support the development and clinical production. |
| Boehringer Ingelheim | Germany | Boehringer Ingelheim has signed a contract development and manufacturing agreement with AnGes for the drug substance of their investigational. |
Recent Developments in the Biologics Contract Manufacturing Market
- In April 2026, WuXi Biologics completed the structure of a novel microbial scalable production site in Chengdu and received significant tool shipments, as the contract development and manufacturing organization works toward good manufacturing practices.
- In April 2026, Sun Pharmaceutical Industries signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75bn. The move is set to significantly expand the company's global pharmaceutical manufacturing footprint and strengthen its presence in women's health
Supply Chain Analysis
R&D:
- Research and development (R&D) in biologics contract manufacturing involves cell line development, optimization of upstream and downstream processes, analytical processes advancement for characterization, and formulation research to ensure stability.
- Key Players: Lonza Group Ltd and Samsung Biologics
Manufacturing Processes:
- Biologics contract manufacturing involves complex upstream cell culture, such as fermentation, bioreactors, and downstream purification, like chromatography and filtration, to produce drug substances under cGMP.
- Key Players: WuXi Biologics and FUJIFILM Diosynth Biotechnologies
Patient Services:
- Patient services related to biologics contract manufacturing ensure the efficacy, safety, quality, and timely delivery of complex, life-saving therapies such as monoclonal antibodies, cell therapies, and vaccines to patients.
- Key Players: Boehringer Ingelheim and Catalent, Inc.
Market Growth
The global biologics contract manufacturing market size was estimated at USD 21.85 billion in 2025 and is predicted to increase from USD 23.99 billion in 2026 to approximately USD 55.65 billion by 2035, expanding at a CAGR of 9.8% from 2026 to 2035.
Keypoints
- Company Overview
- Locations Subsidiaries/Geographic reach
- Key Executives
- Company Financials
- Patents registered
- SWOT Analysis
- Applications Catered
- Strategic collaborations
- Recent Developments
- Competitive Benchmarking